Therapy Areas: Autoimmune
Genentech secures first FDA approval for primary membranous nephropathy treatment
16 November 2026 -

Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that it has received US Food and Drug Administration (FDA) approval for Gazyva (obinutuzumab) to treat adults with primary membranous nephropathy (pMN) at risk of disease progression, making it the first and only approved treatment for the condition.

The approval is based on Phase III MAJESTY trial results, which showed that 36.1% of patients receiving Gazyva achieved complete remission of proteinuria after two years, compared with 5.7% for tacrolimus. Overall remission rates were 50% and 12.9%, respectively, with no new safety signals identified.

Primary membranous nephropathy is a rare, chronic autoimmune disease that can cause irreversible kidney damage and progress to kidney failure.

This approval marks Gazyva's third FDA authorisation in immune-mediated kidney diseases, following previous approvals for idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing Gazyva for systemic lupus erythematosus, with a decision expected by December 2026, while a European regulatory decision is anticipated following a positive recommendation from the CHMP.

Login
Username:

Password: